Peter Mac and Affymetrix Initiate Five-Year Translational Research Collaboration
Complete the form below to unlock access to ALL audio articles.
Affymetrix Inc. has announced that it has entered into a five-year collaboration with the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne, Australia, to analyze genomic information across large patient samples.
Under terms of the agreement, Peter Mac researchers will use Affymetrix GeneChip® microarray technology for translational research projects, beginning with studies on ovarian cancer and carcinoma of unknown primaries.
Peter Mac researchers will use Affymetrix GeneChip technology to perform large-scale clinical studies.
The Affymetrix technology will enable them to discover RNA and DNA patterns that can classify, manage and treat complex diseases.
"We are excited about the opportunities created by the Translational Medicine Program, particularly the chance to apply new technologies to help us answer important clinical questions," said Professor David Bowtell, Ph.D., director of research at the Peter MacCallum Cancer Centre.
"We are keen to help our collaborators across Australia gain access to Affymetrix technology, as we continue to develop as a major center for cancer genomics and genetics."
"We also see the program providing opportunities to interact with other centers worldwide that are involved in translational research."
"Affymetrix is excited to be working with a leading research organization such as the Peter MacCallum Cancer Centre to help bring more effective personalized tests and therapies to market faster," said Robert Wells, vice president, International Markets Group and Corporate Affairs at Affymetrix.
"Together, we hope to accelerate clinical research, improve patient care, and open the door to new genomic applications."
